Clinical Compound Bank

Looking to advance your research? Seeking a breakthrough therapy for your patients?


We offer patient ready compounds for novel, clinical and translational research into diseases with significant unmet medical needs. These compounds, which have demonstrated evidence of target coverage and manageable tolerability in humans, provide opportunities for you to explore disease biology, advance medical science and potentially discover novel therapies for patients.

Let’s partner in clinical or translational research

Every scientist involved in medical research knows about the challenges posed by limited resources and expertise, and the hard choices one must make in terms of prioritising research activities.

Interested investigators are invited to:

  • Explore our Clinical Table of Compounds and examine the key properties of any compound/mechanism of interest
  • Learn the process, criteria, and rough timelines for proposal submission through to full project plan development and final approval
  • Submit a short 2-3 page ‘Concept Proposal’.

Additional marketed, biologic and late-stage clinical development compounds are offered via the AstraZeneca Externally Sponsored Scientific Research portal.

30

Investigator-sponsored clinical projects in progress

10

studies already completed




Submitting a clinical research proposal



A word on Intellectual Property

Addressing Intellectual Property (IP) is key to promoting open innovation. It’s essential that we build mutual trust and reward innovation – this means if one party generates IP, they get rewarded and recognized for it. If we create new IP as a result of our collaboration, then we work out how to share it on a case-by-case basis in a way that works for both parties.

Dr. Menelas Pangalos Executive Vice President, Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca



Clinical compounds available

Filter By

Display
Compound Mechanism of action Originating therapeutic area Proposal type CNS Penetrant Target Class Original Indication Route
AZD0328 Mechanism of action Nicotinic acetylcholine receptor alpha 7 (α7 nAChR) agonist Originating therapeutic area CNS Proposal type Clinical & Preclinical CNS Penetrant Yes Target Class Ligand-gated ion channel Original Indication Cognitive impairment Route Oral
AZD1236 Mechanism of action Matrix metalloproteinase 9 & 12 (MMP9,12) inhibitor Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target Class Enzyme Original Indication COPD Route Oral
AZD1656 Mechanism of action Glucokinase (GK; hexokinase 4) activator Originating therapeutic area Metabolic Disease Proposal type Clinical & Preclinical CNS Penetrant Low Target Class Enzyme Original Indication Diabetes Route Oral
AZD1775 Mechanism of action WEE1 G2 checkpoint kinase inhibitor  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Unknown Target Class Kinase Original Indication Advanced Solid Tumours Route Oral
AZD1981 Mechanism of action Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist [prostaglandin D2 (DP2) receptor antagonist] Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target Class GPCR Original Indication Asthma, COPD Route Oral
AZD2014 Mechanism of action Mammalian target of rapamycin (mTOR) serine/threonine kinase (dual TORC1 and TORC2) inhibitor  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Unknown Target Class Kinase Original Indication Solid Tumours Route Oral
AZD4017 Mechanism of action 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor Originating therapeutic area Metabolic Disease Proposal type Clinical & Preclinical CNS Penetrant Low Target Class Enzyme Original Indication Diabetes Route Oral
AZD5069 Mechanism of action Chemokine (C-X-C motif) receptor 2 (CXCR2) antagonist Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Unknown Target Class GPCR Original Indication Asthma Route Oral
AZD5213 Mechanism of action Histamine receptor 3 (H3) antagonist (inverse agonist) Originating therapeutic area CNS Proposal type Clinical & Preclinical CNS Penetrant Yes Target Class GPCR Original Indication Cognition, Daytime Sleepiness, Tourette's Route Oral
AZD5904 Mechanism of action Myeloperoxidase (MPO) inhibitor Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target Class Enzyme Original Indication COPD, MS Route Oral
AZD7325 Mechanism of action Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAAα2,3) positive modulator    Originating therapeutic area CNS Proposal type Clinical & Preclinical CNS Penetrant Yes Target Class Ligand-gated ion channel Original Indication General Anxiety Disorder Route Oral
AZD9150 Mechanism of action Signal transducer and activator of transcription 3 (STAT3) antisense  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Low Target Class Antisense Original Indication Hepatocellular Carcinoma Route IV
AZD9668 Mechanism of action Neutrophil elastase (NE) inhibitor  Originating therapeutic area Inflammation Proposal type Clinical & Preclinical CNS Penetrant Low Target Class Enzyme Original Indication COPD, Cystic Fibrosis Route Oral
Lesogaberan (AZD3355) Mechanism of action Gamma-aminobutyric acid receptor B (GABAB) agonist   Originating therapeutic area GI Proposal type Clinical & Preclinical CNS Penetrant Low Target Class GPCR Original Indication GERD Route Oral
Saracatinib (AZD0530) Mechanism of action Src tyrosine kinase family inhibitor Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Yes Target Class Kinase Original Indication Oncology Route Oral
Zibotentan (ZD4054) Mechanism of action Endothelin receptor A (ETA) antagonist  Originating therapeutic area Oncology Proposal type Clinical & Preclinical CNS Penetrant Low Target Class GPCR Original Indication Castration-Resistant Prostate Cancer (CRPC) Route Oral

Useful information


How do I know that the information I submit to AstraZeneca will remain confidential?

AstraZeneca is committed to the same ethical policy that is practiced during grant and manuscript peer-reviews. We will not use or disclose information you submit, unless you approve in writing, or the information becomes public, is separately received or independently developed.

What are the typical agreement terms?

The AstraZeneca Open Innovation program seeks to utilize terms that facilitate participation, open collaborative brainstorming, problem solving and are consistent with well-established and tested academic-industry agreement structures (e.g., Lambert/miCRA templates in U.K. and NIH/NCATS CRA in U.S.), for example:

  • Pre-existing IP remains with the original owner
  • New IP follows ownership framework taking into account the contribution of each party and where possible using the well-established academic-industry templates
  • Publications are encouraged after allowing AstraZeneca to comment, patent(s) to be filed (if applicable), AstraZeneca confidential information protected
  • If the collaboration generates positive findings, AstraZeneca has option to negotiate a license to advance further towards patient benefit and commercialization
  • For compounds ‘live’ in development, AstraZeneca minimally receives non-exclusive, royalty-free, fully paid license, with the right to sublicense without limitation, for all purposes for project IP.

In general, Collaborative Research Agreement (CRA) and/or Clinical Trial Agreement (CTA) are/is negotiated for an agreed upon Full Project Proposal/Plan.

1.     Ownership of project IP and rewards (e.g., royalties) if positive data found are based on multiple factors including regional/country standards, IP policies and the current development stage/status of the compound.

2.     AstraZeneca has at least an option to negotiate a license for project IP.